CLINICAL TRIALS PROFILE FOR THIOTHIXENE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for THIOTHIXENE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01234454 ↗ | Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI | Completed | University of North Carolina, Chapel Hill | N/A | 2002-01-01 | The general aim is to compare the effects of typical and atypical antipsychotic medication on brain structure and function. A parallel group treatment trial will be utilized to compare the effects of the typical antipsychotic thiothixene versus the atypical antipsychotics risperidone (RIS) and olanzapine (OLZ) on brain structure and function in schizophrenia in an effort to determine the neuroanatomic basis for cognitive pathology in schizophrenia and its amelioration by atypical antipsychotic drugs. |
| NCT02582736 ↗ | Antipsychotics and Risk of Hyperglycemic Emergencies | Completed | Canadian Institutes of Health Research (CIHR) | 2012-04-01 | The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs. | |
| NCT02582736 ↗ | Antipsychotics and Risk of Hyperglycemic Emergencies | Completed | Drug Safety and Effectiveness Network, Canada | 2012-04-01 | The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs. | |
| NCT02582736 ↗ | Antipsychotics and Risk of Hyperglycemic Emergencies | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 2012-04-01 | The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs. | |
| NCT02600741 ↗ | Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) | Completed | Janssen Scientific Affairs, LLC | 2015-07-24 | The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization, psychiatric emergency room (ER) visit, crisis center visit, mobile crisis unit intervention, arrest/incarceration, and suicide or suicide attempt) in patients under their care during a 12 month period. | |
| NCT03158805 ↗ | Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) | Recruiting | Lindner Center of HOPE | Phase 2 | 2017-04-26 | Taken together these data support the hypothesis that liraglutide 3.0 mg sc injection will reduce body weight and improve metabolic variables in obese or overweight patients with BP without worsening psychiatric symptoms. The investigators predict that liraglutide 3.0 mg sc injection will display greater efficacy as compared to placebo in decreasing body weight in patients with BP who are obese or overweight. To prove this hypothesis, investigators will conduct a single-center, randomized, placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide 3.0 mg sc injection in 60 obese or overweight outpatients with stable BP. The investigators have chosen BP rather than another SMI because it is the most common SMI (more common than schizophrenia or schizoaffective disorder) and has a particularly strong association with obesity. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for THIOTHIXENE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for THIOTHIXENE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for THIOTHIXENE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for THIOTHIXENE HYDROCHLORIDE
Sponsor Name
